YOLFTbeta
GA

GALDERMA GROUP AG

GALDY · NYSE · Healthcare / Drug Manufacturers - Specialty & Generic

45.74USD-0.60 (-1.29%)

Price History

Full chart

Market Stats

Previous Close46.34
Open46.00
Day Range45.60 – 46.00
52-Week Range35.47 – 46.65
Volume9.45K
Market Cap53.98B
P/E (TTM)63.42
Forward P/E46.08
EPS0.73
Dividend Yield0.19%
Beta-0.05
50-Day Avg40.40
200-Day Avg40.61

About

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Flemming Ornskov M.B.A., M.D., M.P.H.
  • Employees7.68K
  • HeadquartersZählerweg 10, Zug, Switzerland, 6300, USA
  • Websitehttps://www.galderma.com

Leadership

  • Dr. Flemming Ornskov M.B.A., M.D., M.P.H.CEO & Director · b. 1958
  • Mr. Luigi Felice La CorteChief Financial Officer · b. 1969
  • Mr. Adrian MurphyHead of Global Operations · b. 1970
  • Mr. Emil IvanovHead of Strategy, Investor Relations & ESG
  • Ms. Desislava Lazarova M.D.Global Head of Customer Education & Training

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.44B3.82B4.12B4.44B5.24B
Growth (%)-+11.00%+7.66%+7.85%+18.04%
Cost of Revenue1.03B1.19B1.23B1.35B1.63B
Gross Profit2.41B2.63B2.88B3.08B3.61B
Gross Margin69.99%68.78%70.08%69.48%68.86%
Operating Expense2.05B2.22B2.27B2.41B2.73B
Operating Income357.20M406.00M611.00M678.00M876.00M
Operating Margin10.37%10.62%14.84%15.27%16.71%
EBITDA-624.20M851.00M959.00M1.14B
EBITDA Margin-16.32%20.67%21.60%21.68%
Net Income-154.30M-98.50M-57.00M231.00M613.00M
Net Income Margin-4.48%-2.58%-1.38%5.20%11.70%
R&D342.60M315.90M287.00M260.00M245.00M
R&D as % of Total Revenue9.94%8.26%6.97%5.86%4.67%
Interest Expense352.70M398.40M564.00M356.00M175.00M
Interest Expense % of Total Revenue10.24%10.42%13.70%8.02%3.34%

Balance Sheet

Currency: USD2023-12-312024-12-312025-12-31
Total Assets12.47B12.62B13.39B
Total Liabilities7.10B4.83B5.24B
Total Equity5.37B7.79B8.15B
Cash368.00M457.00M780.00M
Net Debt4.42B2.19B1.83B

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow195.70M111.30M165.00M488.00M1.19B
Capital Expenditure128.00M159.50M153.00M275.00M154.00M
Free Cash Flow67.70M-48.20M12.00M213.00M1.03B
Dividends Paid----41.00M
FCF to OCF34.59%-43.31%7.27%43.65%87.00%
Dividend Paid to FCF----3.98%

Key Statistics & Ratios

Market Cap53.98B
Enterprise Value52.71B
Trailing P/E63.42
Forward P/E46.08
PEG Ratio1.69
Price / Sales9.11
Price / Book6.19
EPS0.73
Book Value7.05
Revenue (TTM)5.92B
Gross Profit (TTM)4.11B
EBITDA1.39B
Profit Margin14.57%
Operating Margin20.24%
Return on Equity10.83%
Return on Assets5.36%
Shares Outstanding1.17B
Shares Float656.33M
Beta-0.05
Dividend Yield0.19%
Dividend Rate0.09
Payout Ratio12.13%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 50.05
  • Strong Buy
    1

Dividends

20261×
0.09Apr 27, 2026
20251×
0.04Apr 28, 2025